Suraksha Diagnostic Share Price Target 2027: What Earnings Say About Rs 391 and Rs 472
- November 6, 2026
- Posted by: Kunal Singla
- Category: Market
Suraksha Diagnostic share price Rs 327.10 (6 November 2026). Base target Rs 391, bull Rs 472, downside risk Rs 265. PE 49.14. 52W range Rs 224.10 to Rs 360.00.
Quick Answer
The Suraksha Diagnostic share price target for 2027 is Rs 391, about 19.5% above the current price of Rs 327.10. The bull case is Rs 472, and the downside risk level, which is not a target, is Rs 265. The base case assumes earnings per share grow 18.1% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 49.14. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing a Suraksha Diagnostic target price for 2027 should start with where the stock sits today. At Rs 327.10 on 6 November 2026, it is 9.1% below its 52-week high of Rs 360.00 and 46.0% above its 52-week low of Rs 224.10. That range spans 61% from low to high, so the entry point matters as much as the Suraksha Diagnostic price forecast itself.
This article builds the Suraksha Diagnostic share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.
Click Here – Get Free Investment Predictions
Suraksha Diagnostic Stock Analysis: Company Overview and Key Stats
Suraksha Diagnostic (NSE: SURAKSHA) has a market capitalisation of Rs 1,722 crore. In FY26 it reported revenue of Rs 313.58 crore and net profit of Rs 31.40 crore. The table collects the figures the Suraksha Diagnostic share price target is built on.
| Metric | Value |
|---|---|
| Company | Suraksha Diagnostic |
| NSE Ticker | SURAKSHA |
| CMP (6 November 2026) | Rs 327.10 |
| 52-Week High | Rs 360.00 |
| 52-Week Low | Rs 224.10 |
| Market Cap | Rs 1,722 crore |
| PE Ratio (TTM) | 49.14 |
| Industry PE | 63.24 |
| Price to Book | 7.03 |
| Return on Equity | 13.15% |
| Debt to Equity | 0.53 |
| EPS (TTM) | Rs 6.73 |
| Dividend Yield | 0.02% |
| 12-Month Base Target | Rs 391 |
| Bull Case | Rs 472 |
| Downside Risk Level (not a target) | Rs 265 |
Why Is Suraksha Diagnostic Share Price Target Set at Rs 391 for 2027?
The arithmetic is short. Trailing EPS of Rs 6.73 grown for one year gives a forward EPS estimate of Rs 7.95, and multiplying it by the unchanged PE of 49.14 gives the Rs 391 base-case Suraksha Diagnostic stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Suraksha Diagnostic Target Price: Five Years of Results
Suraksha Diagnostic grew revenue from Rs 225.50 crore in FY22 to Rs 313.58 crore in FY26, a compound annual growth rate of 8.6%. Net profit grew more slowly, from Rs 23.75 crore to Rs 31.40 crore (7.2% a year), which points to margin pressure alongside the sales growth.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 225.50 | 23.75 | 278.00 | 0.00 |
| FY23 | 193.69 | 6.07 | 1.22 | 0.00 |
| FY24 | 222.26 | 23.13 | 4.43 | 0.00 |
| FY25 | 255.94 | 30.98 | 5.97 | 0.00 |
| FY26 | 313.58 | 31.40 | 6.18 | 0.05 |
FY26 revenue growth was 22.5%, faster than the four-year average of 8.6%, and net profit moved up 1.4%. EPS rose from Rs 4.43 in FY24 to Rs 6.18 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Suraksha Diagnostic converted 10.0% of FY26 revenue into net profit, against 12.1% in FY25, within a five-year range of 3.1% to 12.1%. EBITDA margin was 31.4% in FY26 versus 33.2% in FY25.
In the June 2026 quarter, revenue was Rs 88.74 crore, up 20.7% from the same quarter a year earlier, while net profit of Rs 12.85 crore was up 40.0%. EBITDA came in at Rs 31.53 crore, up 27.9% year on year. The next quarterly result is the first test of whether the earnings assumption holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.53, and shareholders’ equity grew from Rs 149.97 crore in FY22 to Rs 243.48 crore in FY26. Operating cash flow in FY26 was Rs 81.83 crore against capital expenditure of Rs 67.34 crore, leaving free cash flow of Rs 14.49 crore, or 0.8% of the current market capitalisation. In FY25 free cash flow was Rs 21.34 crore.
Valuation Check for the Suraksha Diagnostic Stock Target: PE, Price to Book and ROE
At a PE of 49.14 against an industry PE of 63.24, Suraksha Diagnostic trades at a discount to its industry. Price to book is 7.03 on a book value of Rs 47.01 per share, and return on equity is 13.15%. A PE of 49.14 equals an earnings yield of 2.0%, and the FY26 dividend of Rs 0.05 per share gives a yield of 0.02%.
Shareholding Pattern and Institutional Holding
Promoters held 49.10% of Suraksha Diagnostic in September 2026, and promoter holding has stayed near 49.10% since September 2025. Foreign institutional investors (FII) held 13.97% and domestic institutions (DII) held 21.56%, which puts total institutional holding at 35.53%. FII holding rose from 13.72% in September 2025 to 13.97% in September 2026. Public shareholders own the remaining 15.37%. A meaningful institutional holding adds a layer of research coverage and trading depth.
Suraksha Diagnostic Share Price Targets for the Short Term and 12 Months
Short Term Suraksha Diagnostic Stock Target Levels: Technical Setup
At Rs 327.10 on 6 November 2026, Suraksha Diagnostic trades below its 50-day simple moving average of Rs 328.12 and above its 200-day exponential moving average of Rs 299.76. The 14-day RSI reads 62.7, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 328.12 (50-day simple moving average) and the nearest support is Rs 299.76 (200-day exponential moving average). A sustained move above Rs 328.12 would improve the short-term setup, while a close below Rs 299.76 would shift attention to the next support.
12 Month Suraksha Diagnostic Target Price for 2027
The 12-month target of Rs 391 means a move of 19.5% up from Rs 327.10 over the next 12 months. It would also push the stock above its 52-week high of Rs 360.00. Anyone checking the Suraksha Diagnostic share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.
How EPS Growth and PE Multiple Change the Suraksha Diagnostic Target Price
| EPS Growth | PE 39.31 | PE 49.14 | PE 56.51 |
|---|---|---|---|
| 0.0% (EPS Rs 6.73) | Rs 265 | Rs 331 | Rs 380 |
| 18.1% (EPS Rs 7.95) | Rs 313 | Rs 391 | Rs 449 |
| 24.1% (EPS Rs 8.35) | Rs 328 | Rs 410 | Rs 472 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Suraksha Diagnostic price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Suraksha Diagnostic Stock Target in 2027
Bull Case Rs 472
The bull case Suraksha Diagnostic price target needs EPS growth of 24.1%, which lifts forward EPS to Rs 8.35, and a PE multiple that rises 15% to 56.51. That gives Rs 472, 44.3% above the current price and above the 52-week high of Rs 360.00, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 265
The downside risk level is not a target. It assumes EPS stays flat at Rs 6.73 and the PE falls 20% to 39.31. That gives Rs 265, 19.0% below the current price and above the 52-week low of Rs 224.10.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 24.1% | 56.51 | Rs 472 | +44.3% |
| Base Case | 18.1% | 49.14 | Rs 391 | +19.5% |
| Downside Risk | 0.0% | 39.31 | Rs 265 | -19.0% |
Key Risks to the Suraksha Diagnostic Target Price for 2027
Growth Slowdown Risk for the Suraksha Diagnostic Price Target
Revenue in the June 2026 quarter was up 20.7% year on year, and FY26 revenue growth was 22.5%. If growth slows from here, the EPS estimate behind the Suraksha Diagnostic stock target will need revising.
Liquidity and Size Risk
Suraksha Diagnostic has a market capitalisation of Rs 1,722 crore. Institutional holding is 35.53%, and promoters hold 49.10%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.
Valuation and Margin Risk
Net margin was 10.0% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 49.14 versus an industry PE of 63.24, a de-rating toward the downside-risk PE of 39.31 would cut the price even if earnings hold.
Market and Technical Risk
Technical indicators add short-term risk: the 14-day RSI is 62.7 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time.
How to Invest in Suraksha Diagnostic
Start with the live price and volume. Any Suraksha Diagnostic share price target is only as current as the data behind it, and the data here is as of 6 November 2026, so refresh the Rs 327.10 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Suraksha Diagnostic’s PE, ROE, debt and shareholding in one place.
Check Suraksha Diagnostic fundamentals on the Univest Screener
Then compare the three Suraksha Diagnostic target price scenarios with your own view. If you expect EPS growth below 18.1%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Suraksha Diagnostic live price and get daily stock recommendations.
Conclusion
The Suraksha Diagnostic share price target for 2027 is Rs 391 in the base case, with Rs 472 as the bull case. The support for that view is arithmetic you can check: EPS grew 18.1% a year over FY24 to FY26, and the stock trades at a PE of 49.14. The risks are equally concrete, including a valuation that can de-rate even when earnings hold and a downside scenario that cuts the price 19% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Suraksha Diagnostic Share Price Target 2027
What is the Suraksha Diagnostic share price target for 2027?
Ans. The base-case Suraksha Diagnostic share price target for 2027 is Rs 391, which is 19.5% above the price of Rs 327.10 on 6 November 2026. The bull case is Rs 472 and the downside risk level, which is not a target, is Rs 265. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.
What is the Suraksha Diagnostic share price today?
Ans. As of 6 November 2026, 9:49 AM IST, Suraksha Diagnostic (NSE: SURAKSHA) trades at Rs 327.10, down 1.27% on the day. That is 9.1% below the 52-week high of Rs 360.00 and 46.0% above the 52-week low of Rs 224.10. The market capitalisation of Rs 1,722 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.
Is Suraksha Diagnostic a buy or sell at the current price?
Ans. The data points both ways. On the positive side, EPS has grown 18.1% a year over FY24 to FY26 and the base case implies 19.5% upside; on the cautious side, the valuation can de-rate even when earnings hold, and the downside risk level of Rs 265 is 19% below the current price. Whether Suraksha Diagnostic fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.
What are the bull case target and downside risk level for Suraksha Diagnostic shares?
Ans. The bull case in the Suraksha Diagnostic share price target for 2027 is Rs 472, which assumes 24.1% EPS growth and a PE of 56.51, a 15% re-rating from today’s multiple. That is 44.3% above the current price and above the 52-week high of Rs 360.00, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 265, which assumes flat EPS and a PE of 39.31, 20% lower than today. It sits 19.0% below the current price and above the 52-week low of Rs 224.10, and it marks a risk to watch, not a target.
What are the main risks to the Suraksha Diagnostic price target?
Ans. Four risks matter most for the Suraksha Diagnostic share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 1,722 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 39.31 would cut the price even if earnings hold.
What is the PE ratio of Suraksha Diagnostic and how does it compare with the industry?
Ans. The PE ratio of Suraksha Diagnostic is 49.14, against an industry PE of 63.24, which is a discount to the industry. Price to book is 7.03 and return on equity is 13.15%, and the PE equals an earnings yield of 2.0%. The base case holds the PE unchanged, so the Suraksha Diagnostic share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.
Who owns Suraksha Diagnostic, and what is the promoter holding?
Ans. Promoters held 49.10% of Suraksha Diagnostic in September 2026. FII held 13.97%, DII held 21.56% and the public held 15.37%. Together the two institutional groups hold 35.53%. Shareholding is filed every quarter, so it is worth rechecking after each result.
What were Suraksha Diagnostic’s latest quarterly results?
Ans. In the June 2026 quarter, Suraksha Diagnostic reported revenue of Rs 88.74 crore (up 20.7% year on year) and net profit of Rs 12.85 crore (up 40.0%). For comparison, FY26 full-year revenue growth was 22.5% and net profit moved up 1.4%. Each new quarter either supports or weakens the EPS growth of 18.1% assumed in the base case.
